Drug Profile
Research programme: antibody drug conjugates - Bayer
Alternative Names: HER2-KSPi-ADC; KSP/Eg5/KIF11; TWEAKR-KSPi-ADCLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Bayer
- Class Antineoplastics; Immunoconjugates; Pyrroles
- Mechanism of Action Kinesin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Solid-tumours in Germany
- 29 Mar 2019 Adverse events data from a preclinical trial in Cancer presented at the Annual Meeting of the American Association for Cancer Research (AACR-2019)
- 01 Apr 2017 Preclinical trials in Solid tumours in Germany